{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T13:22:43Z","timestamp":1778937763029,"version":"3.51.4"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2025,8,9]],"date-time":"2025-08-09T00:00:00Z","timestamp":1754697600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,8,9]],"date-time":"2025-08-09T00:00:00Z","timestamp":1754697600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"The Innovation Foundation of The Affiliated Hospital of Chengdu University","award":["CDFYCX202209"],"award-info":[{"award-number":["CDFYCX202209"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82174202"],"award-info":[{"award-number":["82174202"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Med Oncol"],"DOI":"10.1007\/s12032-025-02968-y","type":"journal-article","created":{"date-parts":[[2025,8,9]],"date-time":"2025-08-09T07:35:06Z","timestamp":1754724906000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Tanshinone IIA is synergistic with the PARP inhibitor olaparib in inducing BRCAs-proficient and -deficient triple-negative breast cancer cell apoptosis"],"prefix":"10.1007","volume":"42","author":[{"given":"Qi","family":"Liu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qian","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoxuan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jie","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lizhen","family":"Liang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liang","family":"Kang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yamei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu","family":"Deng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,8,9]]},"reference":[{"key":"2968_CR1","first-page":"12","volume":"74","author":"RL Siegel","year":"2024","unstructured":"Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA Cancer J Clin. 2024;74:12\u201349.","journal-title":"CA Cancer J Clin"},{"key":"2968_CR2","doi-asserted-by":"publisher","first-page":"2329","DOI":"10.1158\/1078-0432.CCR-06-1109","volume":"13","author":"LA Carey","year":"2007","unstructured":"Carey LA, Dees EC, Sawyer L, Gatti L, Moore DT, Collichio F, et al. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res. 2007;13:2329\u201334.","journal-title":"Clin Cancer Res"},{"key":"2968_CR3","volume":"2011","author":"A Gucalp","year":"2011","unstructured":"Gucalp A, Traina TA. Triple-negative breast cancer: adjuvant therapeutic options. Chemother Res Pract. 2011;2011: 696208.","journal-title":"Chemother Res Pract"},{"key":"2968_CR4","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1200\/JCO.2007.14.4147","volume":"26","author":"C Liedtke","year":"2008","unstructured":"Liedtke C, Mazouni C, Hess KR, Andre F, Tordai A, Mejia JA, et al. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol. 2008;26:1275\u201381.","journal-title":"J Clin Oncol"},{"key":"2968_CR5","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1056\/NEJMoa1802905","volume":"379","author":"JK Litton","year":"2018","unstructured":"Litton JK, Rugo HS, Ettl J, Hurvitz SA, Goncalves A, Lee KH, et al. Talazoparib in patients with advanced breast cancer and a germline BRCA mutation. N Engl J Med. 2018;379:753\u201363.","journal-title":"N Engl J Med"},{"key":"2968_CR6","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1056\/NEJMoa1706450","volume":"377","author":"M Robson","year":"2017","unstructured":"Robson M, Im SA, Senkus E, Xu B, Domchek SM, Masuda N, et al. Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. N Engl J Med. 2017;377:523\u201333.","journal-title":"N Engl J Med"},{"key":"2968_CR7","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.cancergen.2024.06.002","volume":"286","author":"D Sonkin","year":"2024","unstructured":"Sonkin D, Thomas A, Teicher BA. Cancer treatments: past, present, and future. Cancer Genet. 2024;286:18\u201324.","journal-title":"Cancer Genet"},{"key":"2968_CR8","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1038\/s41571-024-00966-z","volume":"22","author":"NYL Ngoi","year":"2025","unstructured":"Ngoi NYL, Gallo D, Torrado C, Nardo M, Durocher D, Yap TA. Synthetic lethal strategies for the development of cancer therapeutics. Nat Rev Clin Oncol. 2025;22:46\u201364.","journal-title":"Nat Rev Clin Oncol"},{"key":"2968_CR9","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.dnarep.2018.08.021","volume":"71","author":"AD D'Andrea","year":"2018","unstructured":"D\u2019Andrea AD. Mechanisms of PARP inhibitor sensitivity and resistance. DNA Repair. 2018;71:172\u20136.","journal-title":"DNA Repair"},{"key":"2968_CR10","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1038\/nature03445","volume":"434","author":"H Farmer","year":"2005","unstructured":"Farmer H, McCabe N, Lord CJ, Tutt AN, Johnson DA, Richardson TB, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature. 2005;434:917\u201321.","journal-title":"Nature"},{"key":"2968_CR11","doi-asserted-by":"publisher","first-page":"2787","DOI":"10.1002\/cncr.26576","volume":"118","author":"AR Hartman","year":"2012","unstructured":"Hartman AR, Kaldate RR, Sailer LM, Painter L, Grier CE, Endsley RR, et al. Prevalence of BRCA mutations in an unselected population of triple-negative breast cancer. Cancer. 2012;118:2787\u201395.","journal-title":"Cancer"},{"key":"2968_CR12","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1007\/s10549-015-3293-7","volume":"150","author":"MW Wong-Brown","year":"2015","unstructured":"Wong-Brown MW, Meldrum CJ, Carpenter JE, Clarke CL, Narod SA, Jakubowska A, et al. Prevalence of BRCA1 and BRCA2 germline mutations in patients with triple-negative breast cancer. Breast Cancer Res Treat. 2015;150:71\u201380.","journal-title":"Breast Cancer Res Treat"},{"key":"2968_CR13","doi-asserted-by":"publisher","first-page":"3759","DOI":"10.1158\/1078-0432.CCR-18-0968","volume":"25","author":"PG Pilie","year":"2019","unstructured":"Pilie PG, Gay CM, Byers LA, O\u2019Connor MJ, Yap TA. PARP inhibitors: extending benefit beyond BRCA-mutant cancers. Clin Cancer Res. 2019;25:3759\u201371.","journal-title":"Clin Cancer Res"},{"key":"2968_CR14","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1038\/nature01368","volume":"421","author":"CJ Bakkenist","year":"2003","unstructured":"Bakkenist CJ, Kastan MB. DNA damage activates ATM through intermolecular autophosphorylation and dimer dissociation. Nature. 2003;421:499\u2013506.","journal-title":"Nature"},{"key":"2968_CR15","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1126\/science.1091496","volume":"304","author":"JH Lee","year":"2004","unstructured":"Lee JH, Paull TT. Direct activation of the ATM protein kinase by the Mre11\/Rad50\/Nbs1 complex. Science. 2004;304:93\u20136.","journal-title":"Science"},{"key":"2968_CR16","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1126\/science.1108297","volume":"308","author":"JH Lee","year":"2005","unstructured":"Lee JH, Paull TT. ATM activation by DNA double-strand breaks through the Mre11-Rad50-Nbs1 complex. Science. 2005;308:551\u20134.","journal-title":"Science"},{"key":"2968_CR17","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1016\/j.dnarep.2004.06.001","volume":"3","author":"CH Bassing","year":"2004","unstructured":"Bassing CH, Alt FW. The cellular response to general and programmed DNA double strand breaks. DNA Repair. 2004;3:781\u201396.","journal-title":"DNA Repair"},{"key":"2968_CR18","doi-asserted-by":"publisher","first-page":"42462","DOI":"10.1074\/jbc.C100466200","volume":"276","author":"S Burma","year":"2001","unstructured":"Burma S, Chen BP, Murphy M, Kurimasa A, Chen DJ. ATM phosphorylates histone H2AX in response to DNA double-strand breaks. J Biol Chem. 2001;276:42462\u20137.","journal-title":"J Biol Chem"},{"key":"2968_CR19","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1038\/35050000","volume":"408","author":"JA Downs","year":"2000","unstructured":"Downs JA, Lowndes NF, Jackson SP. A role for Saccharomyces cerevisiae histone H2A in DNA repair. Nature. 2000;408:1001\u20134.","journal-title":"Nature"},{"key":"2968_CR20","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1158\/1535-7163.MCT-19-0474","volume":"19","author":"JPY Mak","year":"2020","unstructured":"Mak JPY, Ma HT, Poon RYC. Synergism between ATM and PARP1 inhibition involves DNA damage and abrogating the G(2) DNA damage checkpoint. Mol Cancer Ther. 2020;19:123\u201334.","journal-title":"Mol Cancer Ther"},{"key":"2968_CR21","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.tranon.2017.01.007","volume":"10","author":"C Wang","year":"2017","unstructured":"Wang C, Jette N, Moussienko D, Bebb DG, Lees-Miller SP. ATM-deficient colorectal cancer cells are sensitive to the PARP inhibitor olaparib. Transl Oncol. 2017;10:190\u20136.","journal-title":"Transl Oncol"},{"key":"2968_CR22","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.872085","volume":"13","author":"H Zhao","year":"2022","unstructured":"Zhao H, Han B, Li X, Sun C, Zhai Y, Li M, et al. Salvia miltiorrhiza in breast cancer treatment: a review of its phytochemistry, derivatives, nanoparticles, and potential mechanisms. Front Pharmacol. 2022;13: 872085.","journal-title":"Front Pharmacol"},{"key":"2968_CR23","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1002\/med.21304","volume":"34","author":"X Chen","year":"2014","unstructured":"Chen X, Guo J, Bao J, Lu J, Wang Y. The anticancer properties of Salvia miltiorrhiza Bunge (Danshen): a systematic review. Med Res Rev. 2014;34:768\u201394.","journal-title":"Med Res Rev"},{"key":"2968_CR24","doi-asserted-by":"publisher","first-page":"1226","DOI":"10.3389\/fphar.2019.01226","volume":"10","author":"YS Lin","year":"2019","unstructured":"Lin YS, Shen YC, Wu CY, Tsai YY, Yang YH, Lin YY, et al. Danshen improves survival of patients with breast cancer and dihydroisotanshinone I induces ferroptosis and apoptosis of breast cancer cells. Front Pharmacol. 2019;10:1226.","journal-title":"Front Pharmacol"},{"key":"2968_CR25","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2020.611087","volume":"11","author":"ZY Fang","year":"2020","unstructured":"Fang ZY, Zhang M, Liu JN, Zhao X, Zhang YQ, Fang L. Tanshinone IIA: a review of its anticancer effects. Front Pharmacol. 2020;11: 611087.","journal-title":"Front Pharmacol"},{"key":"2968_CR26","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1142\/S0192415X22500070","volume":"50","author":"W Zhang","year":"2022","unstructured":"Zhang W, Liu C, Li J, Lu Y, Li H, Zhuang J, et al. Tanshinone IIA: new perspective on the anti-tumor mechanism of a traditional natural medicine. Am J Chin Med. 2022;50:209\u201339.","journal-title":"Am J Chin Med"},{"key":"2968_CR27","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1038\/s41420-023-01622-8","volume":"9","author":"Y Cao","year":"2023","unstructured":"Cao Y, Tang H, Wang G, Li P, Song Z, Li W, et al. Targeting survivin with Tanshinone IIA inhibits tumor growth and overcomes chemoresistance in colorectal cancer. Cell Death Discov. 2023;9:351.","journal-title":"Cell Death Discov"},{"key":"2968_CR28","doi-asserted-by":"publisher","DOI":"10.1002\/jbt.23851","volume":"38","author":"S Li","year":"2024","unstructured":"Li S, FeiyuTeng, Zhang J, Zhang P, Li M, Wang X, et al. Tanshinone IIA potentiates the chemotherapeutic effect of doxorubicin against breast cancer cells and attenuates the cardiotoxicity of doxorubicin by regulating ERK1\/2 pathway. J Biochem Mol Toxicol. 2024;38: e23851.","journal-title":"J Biochem Mol Toxicol"},{"key":"2968_CR29","doi-asserted-by":"publisher","first-page":"2298","DOI":"10.1002\/ptr.6392","volume":"33","author":"XZ Liao","year":"2019","unstructured":"Liao XZ, Gao Y, Huang S, Chen ZZ, Sun LL, Liu JH, et al. Tanshinone IIA combined with cisplatin synergistically inhibits non-small-cell lung cancer in vitro and in vivo via down-regulating the phosphatidylinositol 3-kinase\/Akt signalling pathway. Phytother Res. 2019;33:2298\u2013309.","journal-title":"Phytother Res"},{"key":"2968_CR30","doi-asserted-by":"publisher","first-page":"555","DOI":"10.3892\/etm.2011.441","volume":"3","author":"CC Su","year":"2012","unstructured":"Su CC. Tanshinone IIA potentiates the efficacy of 5-FU in Colo205 colon cancer cells in vivo through downregulation of P-gp and LC3-II. Exp Ther Med. 2012;3:555\u20139.","journal-title":"Exp Ther Med"},{"key":"2968_CR31","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1158\/0008-5472.CAN-09-1947","volume":"70","author":"TC Chou","year":"2010","unstructured":"Chou TC. Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res. 2010;70:440\u20136.","journal-title":"Cancer Res"},{"key":"2968_CR32","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1016\/j.joim.2023.11.004","volume":"21","author":"Y Zhong","year":"2023","unstructured":"Zhong Y, Zhang BW, Li JT, Zeng X, Pei JX, Zhang YM, et al. Ethanol extract of Herpetospermum caudigerum Wall ameliorates psoriasis-like skin inflammation and promotes degradation of keratinocyte-derived ICAM-1 and CXCL9. J Integr Med. 2023;21:584\u201392.","journal-title":"J Integr Med"},{"key":"2968_CR33","doi-asserted-by":"publisher","first-page":"R47","DOI":"10.1186\/bcr3147","volume":"14","author":"S Knappskog","year":"2012","unstructured":"Knappskog S, Chrisanthar R, Lokkevik E, Anker G, Ostenstad B, Lundgren S, et al. Low expression levels of ATM may substitute for CHEK2 \/TP53 mutations predicting resistance towards anthracycline and mitomycin chemotherapy in breast cancer. Breast Cancer Res. 2012;14:R47.","journal-title":"Breast Cancer Res"},{"key":"2968_CR34","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1158\/1535-7163.MCT-11-0024","volume":"10","author":"J Millour","year":"2011","unstructured":"Millour J, de Olano N, Horimoto Y, Monteiro LJ, Langer JK, Aligue R, et al. ATM and p53 regulate FOXM1 expression via E2F in breast cancer epirubicin treatment and resistance. Mol Cancer Ther. 2011;10:1046\u201358.","journal-title":"Mol Cancer Ther"},{"key":"2968_CR35","doi-asserted-by":"publisher","first-page":"3024","DOI":"10.1038\/onc.2011.21","volume":"30","author":"D Palmieri","year":"2011","unstructured":"Palmieri D, Valentino T, D\u2019Angelo D, De Martino I, Postiglione I, Pacelli R, et al. HMGA proteins promote ATM expression and enhance cancer cell resistance to genotoxic agents. Oncogene. 2011;30:3024\u201335.","journal-title":"Oncogene"},{"key":"2968_CR36","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1093\/annonc\/mdz012","volume":"30","author":"ME Robson","year":"2019","unstructured":"Robson ME, Tung N, Conte P, Im SA, Senkus E, Xu B, et al. OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician\u2019s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer. Ann Oncol. 2019;30:558\u201366.","journal-title":"Ann Oncol"},{"key":"2968_CR37","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1016\/j.tcb.2019.07.008","volume":"29","author":"SM Noordermeer","year":"2019","unstructured":"Noordermeer SM, van Attikum H. PARP inhibitor resistance: a tug-of-war in BRCA-mutated cells. Trends Cell Biol. 2019;29:820\u201334.","journal-title":"Trends Cell Biol"},{"key":"2968_CR38","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1038\/s41571-021-00532-x","volume":"18","author":"MP Dias","year":"2021","unstructured":"Dias MP, Moser SC, Ganesan S, Jonkers J. Understanding and overcoming resistance to PARP inhibitors in cancer therapy. Nat Rev Clin Oncol. 2021;18:773\u201391.","journal-title":"Nat Rev Clin Oncol"},{"key":"2968_CR39","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1186\/1756-9966-32-95","volume":"32","author":"MS Gilardini Montani","year":"2013","unstructured":"Gilardini Montani MS, Prodosmo A, Stagni V, Merli D, Monteonofrio L, Gatti V, et al. ATM-depletion in breast cancer cells confers sensitivity to PARP inhibition. J Exp Clin Cancer Res. 2013;32:95.","journal-title":"J Exp Clin Cancer Res"},{"key":"2968_CR40","doi-asserted-by":"publisher","first-page":"4578","DOI":"10.1182\/blood-2010-01-265769","volume":"116","author":"VJ Weston","year":"2010","unstructured":"Weston VJ, Oldreive CE, Skowronska A, Oscier DG, Pratt G, Dyer MJ, et al. The PARP inhibitor olaparib induces significant killing of ATM-deficient lymphoid tumor cells in vitro and in vivo. Blood. 2010;116:4578\u201387.","journal-title":"Blood"},{"key":"2968_CR41","doi-asserted-by":"publisher","first-page":"3040","DOI":"10.1158\/0008-5472.CAN-16-3398","volume":"77","author":"A Schmitt","year":"2017","unstructured":"Schmitt A, Knittel G, Welcker D, Yang TP, George J, Nowak M, et al. ATM deficiency is associated with sensitivity to PARP1- and ATR inhibitors in lung adenocarcinoma. Cancer Res. 2017;77:3040\u201356.","journal-title":"Cancer Res"},{"key":"2968_CR42","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.7150\/ijbs.41246","volume":"16","author":"L Bian","year":"2020","unstructured":"Bian L, Meng Y, Zhang M, Guo Z, Liu F, Zhang W, et al. ATM expression is elevated in established radiation-resistant breast cancer cells and improves DNA repair efficiency. Int J Biol Sci. 2020;16:1096\u2013106.","journal-title":"Int J Biol Sci"},{"key":"2968_CR43","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1158\/0008-5472.CAN-19-1807","volume":"80","author":"AH Rezaeian","year":"2020","unstructured":"Rezaeian AH, Khanbabaei H, Calin GA. Therapeutic potential of the miRNA-ATM axis in the management of tumor radioresistance. Cancer Res. 2020;80:139\u201350.","journal-title":"Cancer Res"},{"key":"2968_CR44","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1007\/s11523-025-01136-6","volume":"20","author":"EA Ampolini","year":"2025","unstructured":"Ampolini EA, Jimenez-Sainz J, Long DT. The development of ATM inhibitors in cancer therapy. Target Oncol. 2025;20:281\u201397.","journal-title":"Target Oncol"},{"key":"2968_CR45","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2024.102808","volume":"129","author":"JH Lee","year":"2024","unstructured":"Lee JH. Targeting the ATM pathway in cancer: opportunities, challenges and personalized therapeutic strategies. Cancer Treat Rev. 2024;129: 102808.","journal-title":"Cancer Treat Rev"},{"key":"2968_CR46","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2023.103662","volume":"28","author":"B Priya","year":"2023","unstructured":"Priya B, Ravi S, Kirubakaran S. Targeting ATM and ATR for cancer therapeutics: inhibitors in clinic. Drug Discov Today. 2023;28: 103662.","journal-title":"Drug Discov Today"},{"key":"2968_CR47","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1517\/13543776.2013.743995","volume":"23","author":"S Xu","year":"2013","unstructured":"Xu S, Liu P. Tanshinone II-A: new perspectives for old remedies. Expert Opin Ther Pat. 2013;23:149\u201353.","journal-title":"Expert Opin Ther Pat"},{"key":"2968_CR48","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2021.770746","volume":"8","author":"H Zhou","year":"2021","unstructured":"Zhou H, Zhao Y, Peng W, Han W, Wang Z, Ren X, et al. Effect of sodium tanshinone IIA sulfonate injection on blood lipid in patients with coronary heart disease: a systematic review and meta-analysis of randomized clinical trials. Front Cardiovasc Med. 2021;8: 770746.","journal-title":"Front Cardiovasc Med"},{"issue":"3","key":"2968_CR49","doi-asserted-by":"publisher","first-page":"153","DOI":"10.37349\/etat.2020.00010","volume":"1","author":"I Naz","year":"2020","unstructured":"Naz I, Merarchi M, Ramchandani S, Khan MR, Malik MN, Sarwar S, et al. An overview of the anti-cancer actions of Tanshinones, derived from Salvia miltiorrhiza (Danshen). Explor Target Anti-tumor Ther. 2020;1(3):153\u201370.","journal-title":"Explor Target Anti-tumor Ther"},{"key":"2968_CR50","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1038\/nm.2377","volume":"17","author":"N Johnson","year":"2011","unstructured":"Johnson N, Li YC, Walton ZE, Cheng KA, Li D, Rodig SJ, et al. Compromised CDK1 activity sensitizes BRCA-proficient cancers to PARP inhibition. Nat Med. 2011;17:875\u201382.","journal-title":"Nat Med"},{"key":"2968_CR51","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.phymed.2018.05.012","volume":"51","author":"Z Xu","year":"2018","unstructured":"Xu Z, Chen L, Xiao Z, Zhu Y, Jiang H, Jin Y, et al. Potentiation of the anticancer effect of doxorubicinin drug-resistant gastric cancer cells by tanshinone IIA. Phytomedicine. 2018;51:58\u201367.","journal-title":"Phytomedicine"}],"container-title":["Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-025-02968-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12032-025-02968-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-025-02968-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T15:49:16Z","timestamp":1757346556000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12032-025-02968-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,9]]},"references-count":51,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2025,9]]}},"alternative-id":["2968"],"URL":"https:\/\/doi.org\/10.1007\/s12032-025-02968-y","relation":{},"ISSN":["1559-131X"],"issn-type":[{"value":"1559-131X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,9]]},"assertion":[{"value":"2 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}],"article-number":"419"}}